Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021

SELL
$19.92 - $31.6 $526,405 - $835,061
-26,426 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$12.16 - $19.77 $1.13 Million - $1.84 Million
-93,062 Reduced 77.88%
26,426 $523,000
Q3 2020

Nov 13, 2020

SELL
$11.25 - $14.75 $180,607 - $236,796
-16,054 Reduced 11.84%
119,488 $1.56 Million
Q2 2020

Aug 14, 2020

BUY
$10.69 - $16.49 $415,327 - $640,669
38,852 Added 40.18%
135,542 $1.54 Million
Q1 2020

Jun 02, 2020

SELL
$9.78 - $29.53 $173,712 - $524,511
-17,762 Reduced 15.52%
96,690 $1.38 Million
Q4 2019

Feb 14, 2020

BUY
$20.93 - $35.1 $183,765 - $308,178
8,780 Added 8.31%
114,452 $3.12 Million
Q3 2019

Nov 14, 2019

SELL
$22.08 - $47.08 $281,917 - $601,117
-12,768 Reduced 10.78%
105,672 $3.03 Million
Q2 2019

Aug 14, 2019

BUY
$22.67 - $35.0 $381,014 - $588,245
16,807 Added 16.54%
118,440 $3.29 Million
Q1 2019

May 15, 2019

SELL
$26.93 - $34.7 $2.63 Million - $3.38 Million
-97,526 Reduced 48.97%
101,633 $3.38 Million
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $71,805 - $120,141
-2,637 Reduced 1.31%
199,159 $5.79 Million
Q3 2018

Nov 14, 2018

SELL
$37.57 - $50.34 $4.47 Million - $5.99 Million
-119,080 Reduced 37.11%
201,796 $9.28 Million
Q2 2018

Aug 14, 2018

SELL
$27.75 - $40.17 $1.28 Million - $1.85 Million
-46,093 Reduced 12.56%
320,876 $12 Million
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $148,013 - $210,545
-5,134 Reduced 1.38%
366,969 $10.8 Million
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $875,491 - $1.14 Million
-30,773 Reduced 7.64%
372,103 $12.8 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $9.67 Million - $14.6 Million
402,876
402,876 $14.6 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.31B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.